Literature DB >> 3106300

In-vitro susceptibility of Pseudomonas species to fifteen antimicrobial agents.

K V Rolston, E A Anaissie, G P Bodey.   

Abstract

The in-vitro susceptibility of four Pseudomonas spp. (P. aeruginosa, P. fluorescens, P. maltophilia and P. putida) to 15 antimicrobials was determined. Ciprofloxacin had the greatest in-vitro activity. Although the susceptibility of the different species to individual agents was quite variable, they tended to be less susceptible to agents such as amikacin, aztreonam, cefoperazone, ceftazidime and piperacillin, already in clinical use at our institution, than to newer agents, not currently in clinical use.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106300     DOI: 10.1093/jac/19.2.193

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.

Authors:  W Kern; E Kurrle
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

2.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

Review 3.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro.

Authors:  M Lecso-Bornet; J Pierre; D Sarkis-Karam; S Lubera; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

5.  Stenotrophomonas maltophilia induced post-cataract-surgery endophthalmitis: Outbreak investigation and clinical courses of 26 patients.

Authors:  S Horster; L Bader; U Seybold; I Eschler; K G Riedel; J R Bogner
Journal:  Infection       Date:  2008-12-05       Impact factor: 3.553

6.  Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer.

Authors:  K V Rolston; M Messer; D H Ho
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 7.  The epidemiology of infections in intensive care units.

Authors:  A M Emmerson
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

8.  Survey of susceptibility to selected antibiotics of Pseudomonas aeruginosa strains isolated from patients with tumor disease and their relationship to serotype.

Authors:  B Zatkovic; J Trupl; V Majtán
Journal:  Folia Microbiol (Praha)       Date:  1993       Impact factor: 2.099

Review 9.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.